Compliance in two medical centers with criteria for use of caspofungin and lipid-based amphotericin B

American Journal of Health-System Pharmacy

Volumn 61, Issue 9, 2004, Pages 915-920

  Bower, Amy N ^a,b   Tang, Helena M ^c,d   Guglielmo, B Joseph ^b  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c PORTLAND VA MEDICAL CENTER   (United States)

^d UCSF Medical Center and Associate Clinical UCSF School of Pharmacy   (United States)

Author keywords

Amphotericin B; Antifungals; Caspofungin; Compliance; Drug use; Hospitals; Kidney failure; Liposomes; Protocols; Toxicity

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; CREATININE; AMPHOTERICIN B; ANTIFUNGAL AGENT; CYCLOPEPTIDE; PEPTIDE;

ADULT; ARTICLE; ASPERGILLOSIS; CANDIDIASIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DISEASE ASSOCIATION; DRUG USE; HOSPITAL; HUMAN; KIDNEY FAILURE; MYCOSIS; NEPHROTOXICITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RISK FACTOR; TREATMENT INDICATION; PRACTICE GUIDELINE; RETROSPECTIVE STUDY; UNITED STATES;

ADULT; AMPHOTERICIN B; ANTIFUNGAL AGENTS; CALIFORNIA; GUIDELINE ADHERENCE; HUMANS; PEPTIDES; PEPTIDES, CYCLIC; RETROSPECTIVE STUDIES;

EID: 3543076355     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/61.9.915     Document Type: Article

References (12)

1. Walsh TJ, Finberg RW, Arndt C et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med. 1999; 340:764-71.
2. Wong-Beringer A, Jacobs RA, Guglielmo BJ. Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin Infect Dis. 1998; 27:603-18.
3. Mora-Duarte J, Betts R, Rotstein C et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med. 2002; 347:2020-9.
4. Bartizal K, Gill CJ, Abruzzo GK et al. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob Agents Chemother. 1997; 41:2326-32.
5. Douglas CM, Abruzzo G, Bowman JC et al. Caspofungin alone or in combination with itraconazole reduces fungal burden in a neutropenic guinea pig model of disseminated aspergillosis. Paper presented at 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA; 2002 Sep 27-30.
6. Arikan S, Lozano-Chiu M, Paetznick V et al. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother. 2002; 46:245-7.
7. Petraitis V, Petraitiene R, Sarafandi AA et al. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J Infect Dis. 2003; 187:1834-43.
8. Gentina T, De Botton S, Alfandari S et al. Combination antifungals for treatment of pulmonary invasive aspergillosis (IA) refractory to amphotericin B (AmB) in leukaemia patients. Paper presented at 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA; 2002 Sep 27-30.
9. Kontoyiannis DP, Hachem R, Lewis RE et al. Efficacy and toxicity of the caspofungin/liposomal amphotericin B (CAS/LipoAMB) combination in documented or possible invasive aspergillosis (IA) in patients (pts) with hematologic malignancies. Paper presented at 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA; 2002 Sep 27-30.
10. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16:31-41.
11. Wingard JR, Kubilis P, Lee L et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis. 1999; 29:1402-7.
12. Luber AD, Maa L, Lam M et al. Risk factors for amphotericin B-induced nephrotoxicity. J Antimicrob Chemother. 1999; 43:267-71.